Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results

Rhea-AI Summary

Oncternal Therapeutics (Nasdaq: ONCT) announced it will report its first quarter 2022 financial results on May 5, 2022, after market close. The management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a comprehensive business update. Oncternal focuses on developing innovative oncology therapies targeting unmet medical needs, particularly in hematological malignancies and prostate cancer. Its clinical pipeline includes therapies such as zilovertamab and ONCT-808.

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2022 financial results after the U.S. financial markets close on Thursday, May 5, 2022. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.

The live webcast of the call will be available online at investor.oncternal.com and the call will be archived there for at least 30 days.

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The clinical pipeline includes zilovertamab, an investigational monoclonal antibody designed to inhibit ROR1, a type I tyrosine kinase-like orphan receptor. Zilovertamab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), in investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The early-stage pipeline also includes ONCT-534 , a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases. More information is available at https://oncternal.com/.

Contact Information:

Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com

Media
Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
cdavis@lifesciadvisors.com

FAQ

When will Oncternal Therapeutics report its Q1 2022 financial results?

Oncternal Therapeutics will report its Q1 2022 financial results on May 5, 2022, after market close.

What time is the Oncternal Therapeutics webcast for Q1 2022 results?

The webcast for Oncternal Therapeutics' Q1 2022 results will be held at 2:00 p.m. PT (5:00 p.m. ET) on May 5, 2022.

What is Oncternal Therapeutics focused on?

Oncternal Therapeutics focuses on developing novel oncology therapies for cancers with critical unmet needs, particularly in hematological malignancies and prostate cancer.

What therapies are included in Oncternal's clinical pipeline?

Oncternal's clinical pipeline includes therapies such as zilovertamab and ONCT-808, targeting ROR1 for hematologic cancers and solid tumors.